Laboratory Values

mg/dL (min used: 1.0)
International Normalized Ratio (min used: 1.0)
mg/dL (min used: 1.0 · max used: 4.0)
mEq/L (capped at 125–137 for MELD-Na)
🫀
Enter bilirubin, INR, creatinine,
and sodium to calculate MELD
⚕️ Clinical Disclaimer: MELD was developed for cirrhosis and end-stage liver disease. It is less accurate in acute liver failure, hepatocellular carcinoma (MELD exception points apply), and non-cirrhotic liver disease. Values should be entered in US units (mg/dL for bilirubin/creatinine, INR, mEq/L for sodium). This calculator does not account for MELD exception points used in organ allocation.

About the MELD Score

The Model for End-Stage Liver Disease (MELD) score was originally developed to predict 3-month mortality after transjugular intrahepatic portosystemic shunting (TIPS) and was adopted by UNOS in 2002 to prioritize liver transplant allocation. It replaced the Child-Pugh score for organ allocation due to its objectivity — all variables are laboratory-based, eliminating subjective clinical assessments.

MELD Formula

MELD = 3.78 × ln(bilirubin) + 11.2 × ln(INR) + 9.57 × ln(creatinine) + 6.43

Floor values: bilirubin, INR, and creatinine all floored at 1.0 mg/dL. Creatinine capped at 4.0 mg/dL (also set to 4.0 if dialysis ≥2× in past week). Score rounded to nearest integer.

MELD-Na Formula

MELD-Na = MELD + 1.32 × (137 − Na) − [0.033 × MELD × (137 − Na)]

Sodium is constrained to 125–137 mEq/L. MELD-Na capped at 40. Used by UNOS since 2016 for deceased donor liver allocation — it better captures mortality risk from hyponatremia in cirrhosis.

90-Day Mortality Estimates

MELD Score90-Day MortalityClinical Context
<10~1.9%Compensated cirrhosis; outpatient management
10–19~6.0%Moderate disease; close outpatient monitoring
20–29~19.6%Decompensated; transplant evaluation warranted
30–39~52.6%Severe; active transplant listing consideration
≥40~71.3%Critical; high-urgency listing (Status 1A/1B criteria)

Transplant Listing Threshold

UNOS data suggest that the survival benefit of liver transplantation begins to exceed the surgical mortality risk at a MELD ≥15. Below this threshold, the risk of transplant may outweigh the benefit in otherwise stable patients. Most transplant centers use MELD ≥15 as the threshold for active listing consideration.

Patients with hepatocellular carcinoma (HCC) meeting Milan criteria may receive MELD exception points to reflect their malignancy-related risk not captured by laboratory MELD.

References

Malinchoc M, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–871.

Kim WR, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–1026.